ReviewNature reviews. Neurology2015
Restless legs syndrome-current therapies and management of augmentation.
Review in Nature reviews. Neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Restless legs syndrome as a comorbidity in amyotrophic lateral sclerosis: a systematic review and meta-analysis.BMC neurology · 2025Pooled it
- Effects of a 12-week yoga versus a 12-week educational film intervention on symptoms of restless legs syndrome and related outcomes: an exploratory randomized controlled trial.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020Trial
- Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.Movement disorders : official journal of the Movement Disorder Society · 2017Trial
- Trial
- Trial
- Pathophysiology and pharmacological management for sleep problems in Parkinson's disease.Journal of Parkinson's disease · 2026Review
- Polygenic risk scores in neurological disorders: restless legs syndrome as a translational model.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2026Article
- Treatment of restless legs syndrome by acupuncture combined with medicine based on pathophysiological mechanism.Frontiers in medicine · 2026Review
- The evolving treatment landscape of restless legs syndrome.Therapeutic advances in neurological disorders · 2026Review
- Effect of Vibration, Electrical Stimulation and Other Non-Pharmacological Interventions on Restless Leg Syndrome Severity and Sleep Quality: A Systematic Review and Meta-Analysis.Annals of Indian Academy of Neurology · 2025Article
- Pharmacological Strategies for the Treatment of Restless Legs Syndrome.Current neurology and neuroscience reports · 2025Review
- Incidence of Opioid Use Before and After Parkinson's Disease Diagnosis.European journal of pain (London, England) · 2025Article
- Sleep-Related Disorders in Parkinson's Disease: Mechanisms, Diagnosis, and Therapeutic Approaches.CNS & neurological disorders drug targets · 2025Review
- Unraveling Restless Legs Syndrome: A Comprehensive Review of Current Research and Future Directions.International journal of general medicine · 2025Review
- Association of dietary selenium intake and all-cause mortality of Parkinson's disease and its interaction with blood cadmium level: a retrospective cohort study.BMC geriatrics · 2024Article
- A novel opioid/pramipexole combination treatment for the management of acute pain: a pilot study.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- Effects of iron-deficient diet on sleep onset and spinal reflexes in a rodent model of Restless Legs Syndrome.Frontiers in neurology · 2023Article
- Restless legs syndrome: An overview of pathophysiology, comorbidities and therapeutic approaches (Review).Experimental and therapeutic medicine · 2022Review
- Management of Sleep Disturbances in Parkinson's Disease.Journal of Parkinson's disease · 2022Review
- Pharmacologic Treatment of Restless Legs Syndrome.Current neuropharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic restless legs syndrome (RLS) can severely affect quality of life and disturb sleep, so that pharmacological treatment is necessary, especially for elderly patients. Treatment guidelines recommend initiation of therapy with dopamine agonists (pramipexole, ropinirole or the rotigotine transdermal patch, all approved in most countries) or α-2-δ ligands (gabapentin enacarbil, approved in the USA and Japan), depending on the country and availability. Where approved, opioids (prolonged release oxycodone-naloxone, approved in Europe) are also recommended as a second-line therapy for severe RLS. Several iron formulations can be effective but are not yet approved for RLS therapy, whereas benzodiazepines and other anticonvulsants are not recommended or approved. Less is known about effective management of RLS that is associated with other conditions, such as uraemia or pregnancy. Furthermore, very little data are available on the management of RLS when first-line treatment fails or patients experience augmentation. In this Review, we summarize state-of-the-art therapies for RLS in the context of the diagnostic criteria and available guidelines, based on knowledge ranging from Class I evidence for the treatment of idiopathic RLS to Class IV evidence for the treatment of complications such as augmentation. We consider therapies, including combination therapies, that are used in clinical practice for long-term management of RLS, despite a lack of trials and approval, and highlight the need for practical long-term evaluation of current trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.